Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Total Current Liabilities (2019 - 2025)

Bioadaptives' Total Current Liabilities history spans 7 years, with the latest figure at $1.6 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 14.16% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.6 million, down 14.16%, while the annual FY2024 figure was $1.7 million, 1.42% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $1.6 million at Bioadaptives, up from $1.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.9 million in Q2 2024 and bottomed at $1.2 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $1.6 million (2025), against an average of $1.6 million.
  • The largest annual shift saw Total Current Liabilities grew 27.53% in 2022 before it dropped 27.07% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $1.2 million in 2021, then increased by 19.91% to $1.5 million in 2022, then rose by 17.59% to $1.8 million in 2023, then decreased by 1.42% to $1.7 million in 2024, then dropped by 7.89% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Total Current Liabilities are $1.6 million (Q3 2025), $1.4 million (Q2 2025), and $1.7 million (Q1 2025).